1. Home
  2. LUCY vs LGVN Comparison

LUCY vs LGVN Comparison

Compare LUCY & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$0.92

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.77

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCY
LGVN
Founded
2017
2014
Country
United States
United States
Employees
13
N/A
Industry
Ophthalmic Goods
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
34.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LUCY
LGVN
Price
$0.92
$0.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
70.0K
372.7K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.76
EPS
N/A
N/A
Revenue
N/A
$709,000.00
Revenue This Year
$175.92
N/A
Revenue Next Year
$205.56
$10.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.48
52 Week High
$2.90
$1.80

Technical Indicators

Market Signals
Indicator
LUCY
LGVN
Relative Strength Index (RSI) 34.59 43.60
Support Level $0.90 $0.74
Resistance Level $1.07 $0.86
Average True Range (ATR) 0.04 0.06
MACD -0.01 0.01
Stochastic Oscillator 7.45 53.80

Price Performance

Historical Comparison
LUCY
LGVN

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: